Grzegorz S. Nowakowski, M.D., hematologist and oncologist at Mayo Clinic Comprehensive Cancer Center, explains the rapid advancements made in the treatment of large B-cell lymphoma. With unprecedented access to novel agents, lymphoma clinicians are now developing treatment plans such as CAR-T cell therapy and drug antibody conjugates.
With the high stakes surrounding this potentially curable disease, physicians at Mayo Clinic can use state-of-the-art treatments, as well as connect patients with a host of clinical trials. When possible, Dr. Nowakowski can even set a care plan that allows a patient with B-cell lymphoma to receive treatment at home.
this is an extremely exciting time in the treatment of the fuel cell lymphoma. Just in the last couple of years, we had multiple new agents approved to management of patients with relapsed and refractory disease including car T cell therapies and multiple drug antibiotic congregates and antibodies combined with images as well in this space. So our treatment options for patients with relapsed refractory disease had expanded quite significantly. In addition, just recently there were several reports now of studies in the frontline setting which will likely change our practice how we treat patients in the front line and in patients with relapsed and refractory disease. In the second line car T cells will likely move to the second line therapy as well. Therapy of the fuselage piece of lymphoma is rapidly evolving. It is different now there was just a year ago the new drugs on the way to be approved even in a standard setting. But we also have now unprecedented access to novel agents which for the patients and refractory lymphoma which we did not have before. So there's a huge value uh to the referral because number one you can get the opinion what's the state of the art treatment for your patient. But number two, we can actually see the patient will be a candidate for any of the ongoing trials and benefit from this progress which we had made in the last years in treatment of the fuel cell lymphoma. We have access to multiple clinical trials ranging from trials in the frontline setting through cell therapy trials to transfer patients with relapsed refractory disease or even very early clinical trials for the patients who exhausted other therapy options, complexity of lymphoma and the fact that most of the general colleges are not seeing necessarily all of lymphoma patients. Early referral will be preferred in the world cup of lymphoma. We can then help with staging and pathology review as well as designing the initial traffic plan in case of the future beastie lymphoma. The stakes are here pretty high because it's a potential incurable lymphoma. So I would like to rule out the presence of Mick and BCL two or BCL six. Translocation should be double hit lymphoma, which typically would require more escalated therapy at Mayo. We are fortunate that we have this subspecialty expertise. If I see a patient with a rare form of cardiac dysfunction or arrhythmia, actually actually preferred into a world class expert in a cardiology. This really brings additional level of expertise to management of this very complex patients. I think most of the providers are interested in referring the patients and getting the second opinion relatively quickly and then because of the access to staging studies and access to other subspecialties as well as the Mayo system, uh we can come up with the treatment recommendations relatively quickly. After the treatment recommendations are done, we are discussing the treatment can be done locally and frequently if it's a standard of care treatment. This can be easily done locally